The implementation of rifapentine and isoniazid (3HP) in two remote Arctic communities with a predominantly Inuit population, the Taima TB 3HP study

Background: The incidence of TB among Inuit is the highest in Canada. A significantly shorter latent TB infection (LTBI) treatment with rifapentine and isoniazid once weekly for 12 weeks (3HP) is now available in limited settings in Canada. Methods: A prospective open-label 2-year observational pos...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Int J Circumpolar Health
Autors principals: Alvarez, G. G., Van Dyk, D., Mallick, R., Lesperance, S., Demaio, P., Finn, S., Potvin, S. Edmunds, Patterson, M., Pease, C., Amaratunga, K., Hui, C., Cameron, D.W., Mulpuru, S., Aaron, S.D., Momoli, F., Zwerling, A.
Format: Artigo
Idioma:Inglês
Publicat: Taylor & Francis 2020
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7241515/
https://ncbi.nlm.nih.gov/pubmed/32379538
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/22423982.2020.1758501
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars